[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Hepatitis Drug Development Pipeline Analysed by GBI Research in Its New Topical Report Recently Uploaded at MarketPublishers.com

25 Aug 2017 • by Natalie Aster

LONDON – Hepatitis is a contagious viral infection that affects the liver; it may spread on contact with infected blood. Hepatitis may progress as a mild condition or may extend for a longer period of time and lead to different complications. The key symptoms of Hepatitis comprise fatigue, abdominal pain, jaundice, fever, nausea, vomiting, loss of appetite, etc. The typical predisposing factors of this disease include organ transplant, blood transfusion, dialysis and the offspring of an infected mother.

Due to differences in prevalence, type A and D of Hepatitis have far smaller pipelines that type B and C. The size of drug pipelines ranges from 7 products in Hepatitis A to 182 products in Hepatitis B and 199 products in Hepatitis C. Many players that are active in the fields of drug development for two larger types of Hepatitis are usually engaged in the development of products for both types simultaneously. Whilst in Hepatitis A, B and D, the key targets are viral surface antigens and interferons; in Hepatitis C a far wider range of proteins is targeted.

New topical report “Hepatitis Drug Development Pipeline Review, 2017” gives a comprehensive overview of the hepatitis pipeline landscape and provides access to valuable, trustworthy data on the therapeutics under development, delves into competitive landscape and offers profiles of the leading players. It covers projects at various stages of development as well as reviews dormant and discounted projects. This research report discusses various pharmaceutical approaches at each stage of the pipeline development within each indication, identifies the most important R&D milestones, traces the recent developments and changes in this field. In addition, this publication outlines the major challenges and opportunities, and gives future forecasts for the short run.

Note that this in-demand report is available at the discounted price until September 1, 2017!

Further details on the discount offer from GlobalData’s brands are available at this page.

Visit GBI Research catalogue to find many other insightful research studies prepared by this publisher. 


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest